Armstrong Advisory Group’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$96.2K Sell
596
-119
-17% -$19.8K 0.01% 348
2026
Q2
$136K Hold
715
– – 0.01% 312
2026
Q1
$141K Sell
715
-1
-0.1% -$193 0.01% 274
2025
Q4
$132K Hold
716
– – 0.01% 273
2025
Q3
$110K Hold
716
– – 0.01% 291
2025
Q2
$100K Buy
716
+6
+0.8% +$841 0.01% 287
2025
Q1
$93K Hold
710
– – 0.01% 282
2024
Q4
$93K Hold
710
– – 0.01% 282
2024
Q3
$111K Sell
710
-21
-3% -$3.39K 0.01% 262
2024
Q2
$114K Buy
731
+21
+3% +$3.16K 0.01% 241
2024
Q1
$95.6K Hold
710
– – 0.01% 258
2023
Q4
$95.6K Hold
710
– – 0.01% 258
2023
Q3
$96.1K Buy
710
+50
+8% +$6.83K 0.01% 243
2023
Q2
$94.4K Hold
660
– – 0.01% 248
2023
Q1
$91.6K Hold
660
– – 0.01% 248
2022
Q4
$89.4K Buy
+660
New +$82.8K 0.01% 248

Other funds holding AZN

Armstrong Advisory Group's AZN Position: Q3 2026 in Review

Armstrong Advisory Group reduced its AstraZeneca (AZN) stake by 17% in Q3 2026, selling an estimated $19.8K and leaving 596 shares worth $96.2K. The position accounts for 0.01% of the portfolio, ranked #348.

Armstrong Advisory Group first reported a position in AZN in Q4 2022 and has held it in 16 quarters since. The position peaked at $141K in Q1 2026. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Armstrong Advisory Group held 596 shares of AstraZeneca worth $96.2K as of Q3 2026.
  • Armstrong Advisory Group sold 119 AstraZeneca shares in Q3 2026, an estimated $19.8K.
  • AstraZeneca made up 0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #348 holding.
  • Armstrong Advisory Group first reported a position in AstraZeneca in Q4 2022 and has held it in 16 quarters since.
  • Armstrong Advisory Group's AstraZeneca position peaked at $141K in Q1 2026.
  • 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.